Design

We expanded what biology can discover and explore.

Constructive opens a vast, untapped chemical space that natural biology and AI cannot reach alone. We use Syn61, the world’s first fully recoded genome, and engineered tRNAs to incorporate entirely new chemical building blocks into protein chains.

New chemistries. New functionalities. Molecules with site-specific conjugation handles, covalent binding capabilities, and properties that simply didn’t exist before. From next-generation therapeutics to advanced materials and sustainable manufacturing, the design possibilities are boundless.

Make

We solved the hardest problem: manufacturing.

Designing a molecule is one thing. Making it at an industrial scale is another — that’s where most promising biologics hit a wall. BioForge is Constructive’s programmable cellular manufacturing platform. It scales the biological production of complex proteins, including long-chain peptides and molecules with multiple non-canonical amino acids and precise properties that conventional synthesis cannot achieve.

Where today’s methods struggle with low yields and can generate thousands of kilograms of toxic byproduct for every kilogram of product, BioForge gives partners a reliable, scalable pathway from advanced molecular design to manufacturable reality.

It changes the question from can we make this? to what should we make next?

Cure

Here’s what becomes possible.

Expanding the genetic code removes the chemical constraints that limit what proteins can do. We incorporate multiple non-canonical amino acids at precise positions to engineer therapeutics with properties that conventional biology cannot access: improved metabolic stability, covalent binding, orally bioavailable peptides, site-specific conjugation.

Therapeutics is our proving ground. Every programme we advance reimagines the medicines and materials of tomorrow.

Partner With Constructive

Constructive collaborates with pharmaceutical and industrial partners to develop next-generation biologics and materials. Together we can design molecules that were once impossible—and manufacture them at scale.

Constructive Insights

Constructive Bio appoints biopharma leader Jim Weissman to its Board of Directors

Constructive Bio, a leading synthetic biology company, today announces the appointment of Jim Weissman to its Board of Directors.

Constructive Bio shortlisted for One Nucleus Awards 2026: best use of emerging technology

Constructive Bio has been shortlisted for the One Nucleus Awards 2026 in the best use of emerging technology category for…

Constructive Bio’s 2025 Milestones in Non-Canonical Amino Acid (ncAA) Biomanufacturing

Constructive Bio’s 2025 achievements in non-canonical amino acid (ncAA) incorporation include expanded platform capabilities, new partnerships, and recognition from Nature…